Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.10 is 84% above its 5-year average of -6.96, near the high end of its 5-year range (-19.83–-1.10).
45.41% above its 12-month average of -2.02.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.29.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.10
EARNINGS PER SHARE (EPS) AVG TTM
-2.02
EARNINGS PER SHARE (EPS) AVG 3Y
-3.33
EARNINGS PER SHARE (EPS) AVG 5Y
-6.96
EARNINGS PER SHARE (EPS) AVG 10Y
-125.00
EARNINGS PER SHARE (EPS) AVG 15Y
-72.20
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+45.41%
CURRENT VS 3Y AVG
+66.99%
CURRENT VS 5Y AVG
+84.21%
CURRENT VS 10Y AVG
+99.12%
CURRENT VS 15Y AVG
+98.48%
CURRENT VS 20Y AVG
N/A
Pulmatrix, Inc.
Market Cap
$5.20M
Earnings Per Share (EPS)
-1.10
TTM Avg
-2.02
3Y Avg
-3.33
5Y Avg
-6.96
Market Cap
$5.23M
Earnings Per Share (EPS)
-2.30
TTM Avg
-6.97
3Y Avg
-88.06
5Y Avg
-105.56
Market Cap
$5.17M
Earnings Per Share (EPS)
-61.25
TTM Avg
-79.52
3Y Avg
-97.16
5Y Avg
-86.80
Market Cap
$5.16M
Earnings Per Share (EPS)
-5.32
TTM Avg
-8.47
3Y Avg
-12.67
5Y Avg
-14.30
Market Cap
$5.28M
Earnings Per Share (EPS)
N/A
TTM Avg
0.00
3Y Avg
-0.12
5Y Avg
-0.11
Market Cap
$5.31M
Earnings Per Share (EPS)
-9.46
TTM Avg
-14.22
3Y Avg
-49.51
5Y Avg
-78.92
Market Cap
$5.33M
Earnings Per Share (EPS)
-1.27
TTM Avg
-3.56
3Y Avg
-24.18
5Y Avg
-53.12
Market Cap
$5.08M
Earnings Per Share (EPS)
-23.70
TTM Avg
-20.75
3Y Avg
-13.28
5Y Avg
-9.32
Market Cap
$5.06M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.61
3Y Avg
-0.43
5Y Avg
-0.43
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pulmatrix, Inc. (PULM) | $5.20M | -1.10 | -2.02 | -3.33 | -6.96 |
| Alzamend Neuro Inc (ALZN)vs › | $5.23M | -2.30 | -6.97 | -88.06 | -105.56 |
| Lunai Bioworks Inc. (LNAI)vs › | $5.17M | -61.25 | -79.52 | -97.16 | -86.80 |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.16M | -5.32 | -8.47 | -12.67 | -14.30 |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.28M | N/A | 0.00 | -0.12 | -0.11 |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.31M | -9.46 | -14.22 | -49.51 | -78.92 |
| Soligenix, Inc. (SNGX)vs › | $5.33M | -1.27 | -3.56 | -24.18 | -53.12 |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.08M | -23.70 | -20.75 | -13.28 | -9.32 |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.06M | N/A | -1.61 | -0.43 | -0.43 |
| Xenetic Biosciences, Inc. (XBIO)vs › | $5.02M | -1.19 | -2.08 | -2.84 | -5.63 |
Trailing EPS (TTM)
$-1.10
Forward EPS (Est.)
$-2.24
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.41 |
| 2024-12-31 | -2.62 |
| 2023-12-31 | -3.87 |
| 2022-12-31 | -5.43 |
| 2021-12-31 | -8.63 |
| 2020-12-31 | -19.83 |
| 2019-12-31 | -24.37 |
| 2018-12-31 | -99.67 |
| 2017-12-31 | -186.42 |
| 2016-12-31 | -375.87 |
| 2015-12-31 | -646.91 |
| 2014-03-31 | -765.72 |
| 2013-03-31 | -130.75 |
| 2012-03-31 | -7.50 |
